drugset
drugset / Trial / NCT04045743

The Benefit of Bermekimab in Patients With Systemic Sclerosis

NCT04045743 ↗

Phase 2 Completed 20 enrolled Hellenic Institute for the Study of Sepsis
RandomizedSequentialQuadruple-blindTreatment

Summary

This is a proof-of concept RCT trying to generate evidence that inhibition of IL-1α through the administration of bermekimab may inhibit progression of SSc.

Timeline

Start
2019-07-19
Primary completion
2021-01-07
Completion
2021-07-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Bermekimab Monoclonal antibody 400 mg —

Indications

systemic sclerosis